NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
AP Rapoport, EA Stadtmauer, GK Binder-Scholl… - Nature medicine, 2015 - nature.com
Despite recent therapeutic advances, multiple myeloma (MM) remains largely incurable.
Here we report results of a phase I/II trial to evaluate the safety and activity of autologous T …
Here we report results of a phase I/II trial to evaluate the safety and activity of autologous T …
Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma
SP D'Angelo, L Melchiori, MS Merchant, D Bernstein… - Cancer discovery, 2018 - AACR
We evaluated the safety and activity of autologous T cells expressing NY-ESO-1c259, an
affinity-enhanced T-cell receptor (TCR) recognizing an HLA-A2–restricted NY-ESO …
affinity-enhanced T-cell receptor (TCR) recognizing an HLA-A2–restricted NY-ESO …
Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen
LM DuBuske, AJ Frew, F Horak… - Allergy and asthma …, 2011 - ingentaconnect.com
Specific immunotherapy is a well-established treatment for allergic rhinoconjunctivitis;
conventional regimens are lengthy, however, reducing convenience and cost-effectiveness …
conventional regimens are lengthy, however, reducing convenience and cost-effectiveness …
Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen
P Patel, T Holdich… - Journal of Allergy and …, 2014 - Elsevier
Background Specific immunotherapy acts to modify the underlying cause of allergic
rhinoconjunctivitis. Addition of adjuvants, such as monophosphoryl lipid A (MPL), might …
rhinoconjunctivitis. Addition of adjuvants, such as monophosphoryl lipid A (MPL), might …
[HTML][HTML] Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer
GR Blumenschein, S Devarakonda… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background ADP-A2M10 specific peptide enhanced affinity receptor (SPEAR) T cells (ADP-
A2M10) are genetically engineered autologous T cells that express a high-affinity melanoma …
A2M10) are genetically engineered autologous T cells that express a high-affinity melanoma …
Open label, non-randomized, multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1c259t in HLA-A2+ patients with synovial sarcoma …
3000 Background: NY-ESO-1 is expressed in~ 70% of synovial sarcomas (SS). NY-ESO-
1c259T cells recognizing an NY-ESO-1 derived peptide complexed with HLA-A* 02 are …
1c259T cells recognizing an NY-ESO-1 derived peptide complexed with HLA-A* 02 are …
Pharmacokinetics of single oral doses of apricitabine, a novel deoxycytidine analogue reverse transcriptase inhibitor, in healthy volunteers
T Holdich, LA Shiveley, J Sawyer - Clinical drug investigation, 2006 - Springer
Background: Apricitabine is a novel deoxycytidine analogue reverse transcriptase inhibitor
that is undergoing clinical development for the treatment of HIV-1 infection. This study was …
that is undergoing clinical development for the treatment of HIV-1 infection. This study was …
Initial safety assessment of MAGE-A10c796TCR T-cells in two clinical trials.
VK Lam, DS Hong, J Heymach, GR Blumenschein… - 2018 - ascopubs.org
3056 Background: MAGE-A10 is expressed in 10-50% of urothelial, melanoma, head and
neck (HNC), and non-small cell lung cancers (NSCLC). Affinity-enhanced autologous MAGE …
neck (HNC), and non-small cell lung cancers (NSCLC). Affinity-enhanced autologous MAGE …
Influence of food on the pharmacokinetics of apricitabine, a novel deoxycytidine analogue reverse transcriptase inhibitor
T Holdich, J Sawyer - Expert Opinion on Pharmacotherapy, 2008 - Taylor & Francis
Objective: Apricitabine is a novel deoxycytidine analogue reverse transcriptase inhibitor with
clinical efficacy against both wild-type and drug-resistant HIV. The objective of this study was …
clinical efficacy against both wild-type and drug-resistant HIV. The objective of this study was …
Genetically engineered NY-ESO-1 specific T cells in HLA-A201+ patients with advanced cancers.
MS Merchant, MC Cristea, EA Stadtmauer, WD Tap… - 2015 - ascopubs.org
TPS3102 Background: NY-ESO-1 (CTAG-1B) is a cancer testis antigen associated with
spontaneous and vaccine-induced immunity that can lead to improved clinical outcomes. NY …
spontaneous and vaccine-induced immunity that can lead to improved clinical outcomes. NY …